1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Technology appraisal guidance [TA578] Published: 01 May 2019

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 143 KB 01 May 2019  

Declaration of interests

  • Register of interests PDF 119 KB 01 May 2019  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 249 KB 28 March 2019  
  • Committee papers PDF 6.28 MB 28 March 2019  
  • Public committee slides PowerPoint 337 KB 28 March 2019  
  • Final appraisal document Managed Access Agreement PDF 360 KB 28 March 2019  

Invitation to participate

  • Final matrix PDF 256 KB 01 March 2018  
  • Equality impact assessment (Scoping) PDF 171 KB 01 March 2018  
  • Final scope PDF 225 KB 01 March 2018  
  • NICE's response to comments on the draft scope and provisional matrix PDF 379 KB 01 March 2018  

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators  
  • Draft scope post referral PDF 336 KB 13 September 2017  
  • Draft matrix post referral PDF 335 KB 13 September 2017